Assessment of antifungal activities of fluconazole and amphotericin b administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 6, 1998, Pages 1382-1386

  Lewis, Russell E ^a   Lund, Brian C ^a   Klepser, Michael E ^a   Ernst, Erika J ^a   Pfaller, Michael A ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0031805820     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.6.1382     Document Type: Article

References (31)

1. Acar, J. F. 1997. Consequences of bacterial resistance to antibiotics in medical practice. Clin. Infect. Dis. 24(Suppl. 1):S17-S18.
2. Atkinson, B. A., R. Bocanegra, A. L. Colombo, and J. R. Graybill. 1994. Treatment of disseminated Torulopsis glabrata infection with DO870 and amphotericin B. Antimicrob. Agents Chemother. 38:1604-1607.
3. Bannatyne, R. M., and R. Cheung. 1977. Discrepant results of amphotericin B assays on fresh versus frozen serum samples. Antimicrob. Agents Chemother. 12:550.
4. Beck-Saugué, C. M., W. R. Jarvis, and the National Nosocomial Infections Surveillance System. 1993. Secular trends in nosocomial primary bloodstream infections in the United States 1980-1990. J. Infect. Dis. 167:1247-1251.
5. Bennett, J. E., W. E. Dismukes, R. J. Duma, G. Medoff, M. A. Sande, H. Gallis, J. Leonard, B. T. Fields, M. Bradshaw, H. Haywood, Z. A. McGee, T. R. Cate, C. G. Cobbs, J. F. Warner, and D. W. Alling. 1979. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N. Engl. J. Med. 301:126-131.
6. Blaser, J., and S. H. Zinner. 1987. In-vitro models for the study of antibiotic activities. Prog. Drug Res. 31:349-381.
7. Blaser, J. 1985. In-vitro model for the simultaneous simulation ot the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl. A): 125-130.
8. Daneshmend, T. K., and D. W. Warnock. 1983. Clinical pharmacokinetics of systemic antifungal drugs. Clin. Pharmacokinet. 8:17-42.
9. Ebert, S. C., and W. A. Craig. 1990. Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design. Infect. Control Hosp. Epidemiol. 6:319-326.
10. Eliopoulos, G. M. 1989. Synergism and antagonism. Infect. Dis. Clin. N. Am. 3:399-405.
11. George, D., D. Kordick, P. Miniter, T. F. Patterson, and V. T. Andriole. 1993. Combination therapy in experimental invasive aspergillosis. Clin. Infect. Dis. 168:692-698.
12. Ghannoum, M. A., B. J. Spellberg, A. S. Ibrahim, J. A. Ritchie, B. Currie, E. D. Spitzer, J. E. Edwards, Jr., and A. Casadevall. 1994. Sterol composition of Cryptococcus neoformans in the presence and absence ot fluconazole. Antimicrob. Agents Chemother. 38:2029-2033.
13. Grant, S. M., and S. P. Clissold. 1990. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycosis. Drugs 39:877-916.
14. Grasson, S., G. Meinardi, I. de Carneri, and V. Tamassia. 1978. New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob. Agents Chemother. 13:570-576.
15. Holmberg, S. D., S. L. Solomon, and P. A. Blake. 1987. Health and economic impact of antimicrobial resistance. Rev. Infect. Dis. 9:1065-1078.
16. Jones, R. N., S. A. Marshall, M. A. Pfaller, W. W. Wilke, R. J. Hollis, M. E. Erwin, M. B. Edmond, R. P. Wenzel, and the SCOPE Hospital Study Group. 1997. Nosocomial enterococcal bloodstream infections in the SCOPE program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. Diagn. Microbiol. Infect. Dis. 29:95-102.
17. Klepser, M. E., E. J. Ernst, M. E. Ernst, R. E. Lewis, and M. A. Pfaller. 1997. Antifungal time-kill curves, influence of test conditions on results, abstr. D-144, p. 109. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
18. Klepser, M. E., E. J. Wolfe, R. N. Jones, C. H. Nightingale, and M. A. Pfaller. 1997. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41:1392-1395.
19. Martin, E., F. Maier, and S. Bhakdi. 1994. Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob. Agents Chemother. 38:1331-1338.
20. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. Ng, T. K., R. C. Chan, F. A. Adeyemi-Doro, S. W. Cheung, and A. F. Cheng. 1996. Rapid high performance liquid chromatographic assay for antifungal agents in human sera. J. Antimicrob. Chemother. 37:465-472.
22. Pearson, R. D., R. T. Steigbigel, H. T. Davis, and S. W. Chapman. 1980. Method for reliable determination of minimal lethal antibiotic concentrations. Antimicrob. Agents Chemother. 18:699-708.
23. Pfaller, M. A. 1996. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin. Infect. Dis. 22(Suppl. 2):S89-S94.
24. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vivo-in vitro correlation for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
25. Schaffer, A., and A. Böhler. 1993. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses 36:421-424.
26. Schmitt, H. J., E. M. Bernard, F. Edwards, and D. Armstrong. 1991. Combination therapy in a model of pulmonary aspergillosis. Mycoses 34:281-285.
27. Sugar, A. M., C. A. Hitchcock, P. F. Troke, and M. Picard. 1995. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob. Agents Chemother. 39:598-601.
28. Sugar, A. M., M. Salibian, and L. Z. Goldani. 1994. Saperconazole therapy of murine disseminated candidiasis: efficacy and interactions with amphotericin B. Antimicrob. Agents Chemother. 38:371-373.
29. Sugar, A. M. 1995. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob. Agents Chemother. 39:1907-1912.
30. Van Der Horst, C. M., M. S. Saag, G. A. Cloud, R. J. Hamill, J. R. Graybill, J. D. Sobel, P. C. Johnson, C. U. Tuazon, T. Kerkering, B. L. Moskovitz, W. G. Powderly, and W. E. Dismukes. 1997. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N. Engl. J. Med. 337:15-21.
31. Wolfe, E. J., M. E. Klepser, and M. A. Pfaller. 1997. Antifungal dynamics of amphotericin B and fluconazole in combination against Candida albicans, effect of exposure time. Pharmacotherapy 17:189. (Abstract 39.)